Sep 2 |
Dollar General, Temu Parent PDD And Super Micro Computer Are Among Top 10 Large Cap Losers Last Week (Aug 25-Aug 31): Are The Others In Your Portfolio?
|
Aug 30 |
Why Neurocrine Biosciences Stock Was Tumbling This Week
|
Aug 29 |
Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock
|
Aug 29 |
Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results
|
Aug 29 |
Neurocrine upped to overweight by Piper, sees '568 as still viable
|
Aug 29 |
Neurocrine reports positive data from Phase II schizophrenia treatment trial
|
Aug 28 |
Neurocrine: Buying Opportunity After Stock Price Drop On Schizophrenia Data
|
Aug 28 |
Neurocrine Biosciences to Participate at Investor Conferences in September
|
Aug 28 |
Neurocrine Biosciences: Disappointing Data From A Key Readout Hits The Stock Hard
|
Aug 28 |
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
|